Conclusion: Distant failure still remains the overwhelming challenge for patients with UPSC. Our observations suggest that better local regional control with no detriment in DM, DFS, and OS is achieved using CCRT compared to SCRT schedule. CCRT addresses both local/regional and systemic disease upfront. Delaying RT until completion of systemic therapy may compromise local/pelvic control. Further, study with larger number of pts and longer follow-up is needed to define the optimal sequencing of combined modality therapy in UPSC.
dose volume histogram (DVH) of CTV and organ at risks (OARs) were compared with the corresponding unperturbed reference plans. Results: For the liver cases, CTV-based optimization is similar to PTVbased optimization methods for both CTV coverage and dose changes in OARs when dealing with beam range and setup uncertainties. Both methods achieve sufficient CTV coverage under the worst-case scenarios. For the lung cases, CTV-based optimization was much more robust to deal with uncertainties than PTV-based optimization. Under the worst-case scenarios, CTV coverage (V100%) was degraded by 40AE18% and 3AE2% for PTV-based and CTV-based optimization method, respectively. Conclusion: Based on a limited patient cohort, CTV-based robustness optimization is much less sensitive to beam range as well as setup uncertainties than PTV-based optimization for lung cases using IMPT. However, in case of liver PTV-based optimization may be sufficient to account for dosimetric and set up uncertainties. This may be due to the fact that lung tumors are surrounded by low density lung tissues, which are more sensitive to the uncertainties in the beam pathway compared to the liver tissues.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.